Metabolic disease does not arrive suddenly. It builds quietly for years — often more than a decade — before any standard test registers a problem. The reason most people are caught late is that the test we rely on to screen for it, HbA1c, is designed to detect the disease near its endpoint, not its beginning. There is an earlier, more sensitive signal. It is rarely measured, and it can change the entire trajectory.

The HbA1c Problem

HbA1c reflects average blood glucose over the preceding two to three months, and it is a fine tool for what it does. The problem is timing. By the moment glucose has risen far enough to push HbA1c into the abnormal range, the underlying machinery has already been failing for years. Estimates suggest that by the time type 2 diabetes is formally diagnosed, 40–50% of pancreatic beta-cell capacity may already be lost. HbA1c, in other words, is a smoke detector that only goes off once a good part of the house has burned.

What Insulin Resistance Actually Is

To understand the earlier signal, you have to understand the mechanism. Insulin is the hormone that tells cells to take up glucose from the blood. In insulin resistance, the tissues — muscle, liver, fat — gradually stop responding to that signal. Glucose struggles to get in. The body's response is not to give up but to shout louder: the pancreas secretes more and more insulin to force the same amount of glucose into increasingly deaf cells.

For a long time, this compensation works. Glucose stays in the normal range — so HbA1c and fasting glucose both look fine — but only because insulin is running far above where it should be. The dysfunction is fully present. It is simply hidden behind a normal glucose number.

The 10–15 Year Gap

This compensatory phase is not brief. Insulin resistance typically precedes a diagnosis of type 2 diabetes by ten to fifteen years. That decade-plus is the most valuable window in all of metabolic medicine — a long stretch during which the disease is reversible with lifestyle change alone, and during which conventional screening sees nothing wrong.

The Hyperinsulinemia Phase

The state of normal glucose with elevated insulin has a name: hyperinsulinemia. It is the window conventional medicine misses, because conventional medicine measures glucose, not insulin. A patient can sail through annual physicals for years — "your sugar is perfect" — while their fasting insulin climbs and the metabolic foundation erodes beneath a reassuring surface.

By the time HbA1c reaches 5.7% — the threshold for "prediabetes" — insulin resistance has typically been present for a decade. The diagnostic label arrives long after the biology has already declared itself.

Measuring It: Fasting Insulin and HOMA-IR

The fix is simple: measure fasting insulin alongside fasting glucose, and combine them into the HOMA-IR index, a validated estimate of insulin resistance.

HOMA-IR = (fasting glucose [mg/dL] × fasting insulin [µIU/mL]) / 405

  • Optimal: HOMA-IR below 1.0 (fasting insulin under 5 µIU/mL).
  • Early insulin resistance: HOMA-IR 1.5–2.5.
  • Overt insulin resistance: HOMA-IR above 2.5.

One caveat is essential. Many labs report a "normal" fasting insulin as anything up to roughly 25 µIU/mL. That is a population normal — a range derived from a population that is itself substantially metabolically unhealthy. It is not a metabolic optimum. A fasting insulin of 18 may be flagged as normal and still represent meaningful, actionable resistance.

CGM as a Complementary Tool

Continuous glucose monitoring adds a dynamic layer that fasting values cannot capture. A CGM reveals postprandial glucose excursions — how high and how fast your glucose spikes after meals — along with time-in-range and overall glycemic variability. Sharp, frequent spikes and wide variability are early behavioural fingerprints of declining insulin sensitivity, visible in real time and long before any fasting marker shifts.

What to Do If Elevated

If fasting insulin or HOMA-IR is elevated, the interventions follow a clear hierarchy of potency:

  • Resistance training and aerobic exercise, first. Skeletal muscle is the largest site of glucose disposal in the body, and contraction improves insulin sensitivity through pathways that do not even require insulin. This is the single most potent lever.
  • Time-restricted eating and carbohydrate quality. Compressing the eating window and reducing refined-carbohydrate load lowers the insulin demand the body must meet.
  • Sleep optimization. Even a few nights of short sleep measurably worsens insulin sensitivity; restoring it is foundational, not optional.
  • Pharmacological adjuncts. Where lifestyle proves insufficient, agents such as metformin or berberine can support insulin sensitivity — as additions to, never replacements for, the steps above.

The point of measuring fasting insulin is not to add another number to a panel. It is to move the moment of detection a decade earlier — into the window where the problem is still fully reversible, and where a small intervention today prevents a large diagnosis tomorrow.